Hi all,
I am a recent shareholder in CHM. I am highly science orientated . I have been investing generally since 1989, but since 2017 I have specialised in baby pharmaceuticals. I do my best scientific DD and then invest. I only look at the science generally.
Anyway, my rationale for picking excellent science is historically in the ASX world, a Company that has outstanding science doesn't get delisted. Many other things may happen though. Appreciate the history of this stock. Exceptional science improves survival odds if I can say that!
If you research my last post on HC, you will see I try to be cutting edge and notice highly science based ideas before others including the scientists sometimes by years it seems.
I have found the best way to explain the science is through laypersons terms and I will endeavour to provide you with my thoughts. I will learn as well, so it's to my benefit and hopefully yours
I intend to document a series of posts explaining from A to Z why we are invested in this particular Company. They take time to write so bare with me. It may take a few weeks to finalise.
I do my utmost to be factual, but I will possibly add some scientific theory on the future.
I will look at various competitors and look at our pros and cons and try to decipher exactly what we have here .
Onto business:
CAR T stands for Chimeric Antigen Receptor T-cell therapy.
It's a laboratory engineered protein added to T cells, enabling them to recognize specific antigens (proteins) on cancer cells.
T cells are a type of white blood cell critical for immune response.
It is called cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
CAR T cells seek out cancer cells bearing the target antigen, attack them directly, and stimulate the immune system for long-term cancer surveillance. A short documentary to explain further.
Time line development:
In the 1960s, early attempts to use T cells to treat transplanted mice tumours were unsuccessful due to an inability to multiply and manipulate the T cells in culture.
Studies in the early 1980s demonstrated that intravenous injection of T cells expanded in IL-2 could treat bulky subcutaneous lymphomas, and the administration of IL-2 after cell transfer increased T cell efficacy.
So in laypersons terms ;
Scientists made an important discovery: they could grow immune cells (T cells) in a lab using a special protein called IL-2 ( interleukin 2), which acts like a growth booster for these cells. When they injected these supercharged T cells into patients with large skin-based lymphomas (a type of cancer), they saw promising results. The IL-2 helped the T cells multiply and stay active, making them better cancer fighters.
After putting these turbocharged T cells back into patients, they found that giving additional IL-2 directly to patients helped the transferred cells work even better. This one-two punch – growing cancer-fighting cells outside the body and then supporting them inside the body – became an early blueprint for modern cell therapies like CAR-T treatments. Think of IL-2 as both a "cell fertilizer" and a "performance booster" for cancer-fighting immune cells.
In the late 1990s: Co-stimulation breakthrough
Researchers discovered that adding co-stimulatory molecules (e.g., CD28) to CARs improved T-cell persistence and anti-cancer efficacy, leading to second-generation CARs. Remember CDH17 is a third generation and that will be explained later in the series.
So in laypersons terms, CAR-T cells (genetically modified cancer fighters) needed an extra power boost to work effectively. They added co-stimulatory molecules – like CD28 – to act as "turbo buttons" for the cells. Think of it like upgrading a car's engine with a second accelerator pedal to make it faster and longer-lasting., so they have added extra time of drug to be in the system, multiply better and have more engine torque.
Think of CD28 as an immune system activator.
So when was CDH17 created?
1994: CDH17 (Cadherin-17) was first cloned from rat liver during basic research on cadherin proteins, though its cancer relevance wasn't yet known.
2010s: Researchers (including Dr. Xianxin Hua's team) discovered CDH17's role in gastrointestinal cancers and its potential as a CAR-T target
2021. Chimeric therapeutic acquired rights to develop CDH17 CAR-T therapy (CHM 2101).
2022: Preclinical data published in Nature Cancer showed CDH17 CAR-T eradicating tumors without harming healthy tissue.
So we have a timeline and history of drug development
More next series ,we shall look at its cellular makeup in today's world . It's a very tricky subject but I will try and explain easily.
Two references for those wishing more knowledge.
https://www.cusabio.com/c-21109.html
https://netrf.org/2024/09/19/historic-car-t-trial-opens-at-university-of-pennsylvania/
Kpax
(20min delay)